Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001181431-11-016796
Filing Date
2011-03-09
Accepted
2011-03-09 16:13:43
Documents
1
Period of Report
2011-03-07

Document Format Files

Seq Description Document Type Size
1 FORM 4 rrd304711.html 4  
1 FORM 4 rrd304711.xml 4 10136
  Complete submission text file 0001181431-11-016796.txt   11534
Mailing Address 3530 TORINGDON WAY SUITE 200 CHARLOTTE NC 28277
Business Address 3530 TORINGDON WAY SUITE 200 CHARLOTTE NC 28277 704-341-1516
Chelsea Therapeutics International, Ltd. (Issuer) CIK: 0001333763 (see all company filings)

EIN.: 203174202 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O OXIGENE, INC., 230 THIRD AVENUE WALTHAM MA 02451
Business Address
Schwieterman William D (Reporting) CIK: 0001403961 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-51462 | Film No.: 11675249